Contact a Rep
CONTACT A REP
Interested in connecting with an ANI Pharmaceuticals representative?

Fill out the request form below if you wish to be contacted with more information on Cortrophin Gel.

This form is for healthcare professionals only. If you are a patient looking to contact customer service, please call 1-800-434-1121 or email info@anipharmaceuticals.com.

* = Required

I confirm and agree to the following:*

I am a licensed US healthcare professional. I understand that this information may be used by ANI Pharmaceuticals and its affiliates and partners or third parties working on behalf of ANI Pharmaceuticals to contact me. I agree that the personal information I provide may be used by ANI Pharmaceuticals, or other companies acting on its behalf, to contact me via mail, email, or otherwise provide me with information about educational materials, market research, products, and services concerning Cortrophin Gel. I give my permission for ANI Pharmaceuticals to use my information for reasonable business purposes as permitted or required by law. Neither ANI Pharmaceuticals nor the companies working on its behalf may sell or rent my personal information except for as set forth in the ANI Pharmaceuticals Privacy Policy.

* = Required

Get helpful resources for you, your office staff, and your patients

The following resources are designed to help support you and your patients on their treatment journey with Cortrophin Gel.

Resources for healthcare providers
Enrollment Forms

Download the appropriate Enrollment Form based on desired vial size to begin the prescription process:

Choose Enrollment Form
Dosing Guide

Download this dosing guide to help teach your patients about dosing and administration.

Understanding the Prescription Process Flashcard

Learn about the prescription and enrollment process in more detail, so you can help patients understand what to expect at every step.

ICD-10 Diagnosis Codes

See a full list of potential ICD-10 Diagnosis Codes.

Consent Form

Download and have your patients fill out this consent form to be contacted about Cortrophin Gel.

Authorization Form

Download and have your patients fill out this HIPAA authorization form.

EnglishSpanish
Prefilled Syringe Overview

Download to get more information about Cortrophin Gel single-dose prefilled syringes.

Resources for in-office administration
Cortrophin Gel is available at select specialty pharmacies
Podiatry and Primary Care Office Staff Cortrophin In Your Corner Brochure
Podiatry and Primary Care Procurement Flashcard

A step-by-step guide from prescribing Cortrophin Gel through your patients receiving it.

Procurement Flashcard

Download this procurement flashcard and ordering guide to identify an appropriate authorized distributor for Cortrophin Gel.

1 mL Billing and Coding Guide

Use this guide for an overview of the coding and billing that may be appropriate when submitting a claim for Cortrophin Gel for a patient diagnosed with an acute gouty arthritis flare.

Medicare Administrative Contractor (MAC) Flashcards
Choose MAC Flashcard
Resources for patients
Vial Injection Guide 

Get a step-by-step guide to administering Cortrophin Gel using the multiple-dose vial. 

EnglishSpanish
Prefilled Syringe Injection Guide

A useful guide on how to inject Purified Cortrophin Gel, with less steps.

EnglishSpanish
Injection Calendar

Use this convenient calendar to help track your treatment schedule. 

EnglishSpanish
Podiatry and Primary Care Patient Cortrophin In Your Corner Brochure

A guide for what to expect while your patient is having their prescription processed.

EnglishSpanish
Vial Injection Training Video 

Watch a step-by-step video about the injection process for administering Cortrophin Gel using the multiple-dose vial. 

Watch Video
Prefilled Syringe Injection Video

Watch a step-by-step video about the injection process for administering Cortrophin Gel using the prefilled syringe.

Watch Video
Patient Education Materials

Provide your patients with valuable education, resources, and helpful information about where Cortrophin Gel may fit into their treatment plan.   

Choose Brochure

QUESTIONS ABOUT COVERAGE AND FINANCIAL SUPPORT OPTIONS?

If you or your patients have questions about coverage and financial support options, please call Cortrophin In Your Corner at 1-800-805-5258, Monday–Friday, 8 AM–8 PM ET

Prescribing
Cortrophin Gel

Access important
enrollment information.

Prescribe & Enroll
About Cortrophin Gel & Dosing

Learn more about Cortrophin Gel and view recommended dosing by indication.

Learn about dosing
Proposed Mechanism
of Action

Discover how ACTH may work by viewing its proposed mechanism of action (MOA).

Learn More
Indications
Important Safety Information
Expand ISI
IndicationsExpand ISI

Cortrophin Gel is a prescription medicine that is injected subcutaneously or intramuscularly. It is indicated for:

Cortrophin Gel is indicated for:

  • Acute exacerbations of multiple sclerosis.
  • Short-term administration as an adjunctive therapy during an acute episode or exacerbation in rheumatoid arthritis, including juvenile rheumatoid arthritis; psoriatic arthritis; ankylosing spondylitis; and acute gouty arthritis.
  • Exacerbations or as maintenance therapy in select cases of systemic lupus erythematosus and systemic dermatomyositis (polymyositis).
  • Severe erythema multiforme (Stevens-Johnson syndrome) and severe psoriasis.
  • Atopic dermatitis and serum sickness.
  • Severe acute and chronic allergic and inflammatory conditions affecting the eye and its adnexa, such as allergic conjunctivitis, keratitis, iritis and iridocyclitis, diffuse posterior uveitis and choroiditis, optic neuritis, chorioretinitis, and anterior segment inflammation.
  • Symptomatic sarcoidosis.
  • Inducing a diuresis or remission of proteinuria due to nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus.
Important Safety InformationExpand ISI
Contraindications
  • Cortrophin Gel is contraindicated for intravenous administration.
  • Cortrophin Gel is contraindicated in patients who have any of the following conditions: scleroderma; osteoporosis; systemic fungal infections; ocular herpes simplex; recent surgery; history of or the presence of a peptic ulcer; congestive heart failure; hypertension; primary adrenocortical insufficiency; adrenocortical hyperfunction; or sensitivity to proteins derived from porcine sources.
Warnings and Precautions
  • Infections: Corticotropin therapy may increase susceptibility to infections and may mask the symptoms of infections.
  • Adrenal insufficiency: Prolonged corticotropin therapy can increase the potential for adrenal insufficiency after withdrawal of the medication. Adrenal insufficiency may be minimized by gradually reducing the corticotropin dosage. Hormone therapy should be reinstituted if stressful situations arise during discontinuation.
  • Elevated blood pressure, salt and water retention, and hypokalemia: Corticotropin can cause elevation of blood pressure, salt and water retention, and increased excretion of potassium or calcium.
  • Masking symptoms of other diseases: Corticotropin may only suppress signs and symptoms of chronic disease without altering the natural course of disease.
  • Psychiatric reactions: Psychic derangements may appear when corticotropin is used, ranging from euphoria, insomnia, mood swings, personality changes, and depression to psychosis. Existing conditions may be aggravated.
  • Ophthalmic reactions: Prolonged use of corticotropin may produce posterior subcapsular cataracts and glaucoma with possible damage to the optic nerves.
  • Immunogenicity potential: Prolonged administration of Cortrophin Gel may increase the risk of hypersensitivity reactions. Cases of anaphylaxis have been reported in the postmarketing setting. Neutralizing antibodies with chronic administration may lead to loss of endogenous ACTH and Cortrophin Gel activity.
  • Vaccination: Patients should not be vaccinated against smallpox while on corticotropin therapy. Other immunizations should be undertaken with caution due to possible neurologic complications and lack of antibody response.
  • Use in patients with hypothyroidism and cirrhosis: There is an enhanced effect in patients with hypothyroidism and in those with cirrhosis.
  • Use in patients with latent tuberculosis or tuberculin reactivity: Closely observe for reactivation of the disease.
  • Comorbid diseases: Corticotropin should be used with caution in patients with diabetes, abscess, pyogenic infections, diverticulitis, renal insufficiency, and myasthenia gravis.
  • Growth and development: Carefully observe growth and development of infants and children on prolonged corticotropin therapy.
  • Acute gouty arthritis: Treatment of acute gouty arthritis should be limited to a few days. Conventional concomitant therapy should be administered during corticotropin treatment and for several days after it is stopped.
  • Drug interactions: Aspirin should be used cautiously with corticotropin in hypoprothrombinemia.
  • Pregnancy: Since fetal abnormalities have been observed in animals, Cortrophin Gel should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Adverse Reactions

Adverse reactions for Cortrophin Gel include fluid or sodium retention; muscle weakness; osteoporosis; peptic ulcer with possible perforation and hemorrhage; injection site reactions; impaired wound healing; hypertension; convulsions; headache; development of Cushingoid state; suppression of growth in children; anaphylaxis (anaphylactic shock, urticaria, respiratory compromise, edema); and weight gain. These are not all the adverse reactions reported with Cortrophin Gel.

Please see full Prescribing Information.

Indications

Cortrophin Gel is a prescription medicine that is injected subcutaneously or intramuscularly. It is indicated for:

Cortrophin Gel is indicated for:

  • Acute exacerbations of multiple sclerosis.
  • Short-term administration as an adjunctive therapy during an acute episode or exacerbation in rheumatoid arthritis, including juvenile rheumatoid arthritis; psoriatic arthritis; ankylosing spondylitis; and acute gouty arthritis.
  • Exacerbations or as maintenance therapy in select cases of systemic lupus erythematosus and systemic dermatomyositis (polymyositis).
  • Severe erythema multiforme (Stevens-Johnson syndrome) and severe psoriasis.
  • Atopic dermatitis and serum sickness.
  • Severe acute and chronic allergic and inflammatory conditions affecting the eye and its adnexa, such as allergic conjunctivitis, keratitis, iritis and iridocyclitis, diffuse posterior uveitis and choroiditis, optic neuritis, chorioretinitis, and anterior segment inflammation.
  • Symptomatic sarcoidosis.
  • Inducing a diuresis or remission of proteinuria due to nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus.
Important Safety InformationContraindications
  • Cortrophin Gel is contraindicated for intravenous administration.
  • Cortrophin Gel is contraindicated in patients who have any of the following conditions: scleroderma; osteoporosis; systemic fungal infections; ocular herpes simplex; recent surgery; history of or the presence of a peptic ulcer; congestive heart failure; hypertension; primary adrenocortical insufficiency; adrenocortical hyperfunction; or sensitivity to proteins derived from porcine sources.
Warnings and Precautions
  • Infections: Corticotropin therapy may increase susceptibility to infections and may mask the symptoms of infections.
  • Adrenal insufficiency: Prolonged corticotropin therapy can increase the potential for adrenal insufficiency after withdrawal of the medication. Adrenal insufficiency may be minimized by gradually reducing the corticotropin dosage. Hormone therapy should be reinstituted if stressful situations arise during discontinuation.
  • Elevated blood pressure, salt and water retention, and hypokalemia: Corticotropin can cause elevation of blood pressure, salt and water retention, and increased excretion of potassium or calcium.
  • Masking symptoms of other diseases: Corticotropin may only suppress signs and symptoms of chronic disease without altering the natural course of disease.
  • Psychiatric reactions: Psychic derangements may appear when corticotropin is used, ranging from euphoria, insomnia, mood swings, personality changes, and depression to psychosis. Existing conditions may be aggravated.
  • Ophthalmic reactions: Prolonged use of corticotropin may produce posterior subcapsular cataracts and glaucoma with possible damage to the optic nerves.
  • Immunogenicity potential: Prolonged administration of Cortrophin Gel may increase the risk of hypersensitivity reactions. Cases of anaphylaxis have been reported in the postmarketing setting. Neutralizing antibodies with chronic administration may lead to loss of endogenous ACTH and Cortrophin Gel activity.
  • Vaccination: Patients should not be vaccinated against smallpox while on corticotropin therapy. Other immunizations should be undertaken with caution due to possible neurologic complications and lack of antibody response.
  • Use in patients with hypothyroidism and cirrhosis: There is an enhanced effect in patients with hypothyroidism and in those with cirrhosis.
  • Use in patients with latent tuberculosis or tuberculin reactivity: Closely observe for reactivation of the disease.
  • Comorbid diseases: Corticotropin should be used with caution in patients with diabetes, abscess, pyogenic infections, diverticulitis, renal insufficiency, and myasthenia gravis.
  • Growth and development: Carefully observe growth and development of infants and children on prolonged corticotropin therapy.
  • Acute gouty arthritis: Treatment of acute gouty arthritis should be limited to a few days. Conventional concomitant therapy should be administered during corticotropin treatment and for several days after it is stopped.
  • Drug interactions: Aspirin should be used cautiously with corticotropin in hypoprothrombinemia.
  • Pregnancy: Since fetal abnormalities have been observed in animals, Cortrophin Gel should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Adverse Reactions

Adverse reactions for Cortrophin Gel include fluid or sodium retention; muscle weakness; osteoporosis; peptic ulcer with possible perforation and hemorrhage; injection site reactions; impaired wound healing; hypertension; convulsions; headache; development of Cushingoid state; suppression of growth in children; anaphylaxis (anaphylactic shock, urticaria, respiratory compromise, edema); and weight gain. These are not all the adverse reactions reported with Cortrophin Gel.

Please see full Prescribing Information.